174 related articles for article (PubMed ID: 11064359)
1. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
Shahin MS; Hughes JH; Sood AK; Buller RE
Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
[TBL] [Abstract][Full Text] [Related]
2. p53 mutations and expression in ovarian cancers: correlation with overall survival.
Wen WH; Reles A; Runnebaum IB; Sullivan-Halley J; Bernstein L; Jones LA; Felix JC; Kreienberg R; el-Naggar A; Press MF
Int J Gynecol Pathol; 1999 Jan; 18(1):29-41. PubMed ID: 9891239
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy.
Nakayama K; Kanzaki A; Terada K; Mutoh M; Ogawa K; Sugiyama T; Takenoshita S; Itoh K; Yaegashi N; Miyazaki K; Neamati N; Takebayashi Y
Clin Cancer Res; 2004 Apr; 10(8):2804-11. PubMed ID: 15102688
[TBL] [Abstract][Full Text] [Related]
4. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
5. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
6. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
7. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
8. p21 expression predicts outcome in p53-null ovarian carcinoma.
Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
[TBL] [Abstract][Full Text] [Related]
9. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
11. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
12. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
13. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
15. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer.
Eltabbakh GH; Belinson JL; Kennedy AW; Biscotti CV; Casey G; Tubbs RR; Blumenson LE
Cancer; 1997 Sep; 80(5):892-8. PubMed ID: 9307189
[TBL] [Abstract][Full Text] [Related]
16. p53 gene analysis of ovarian borderline tumors and stage I carcinomas.
Kupryjanczyk J; Bell DA; Dimeo D; Beauchamp R; Thor AD; Yandell DW
Hum Pathol; 1995 Apr; 26(4):387-92. PubMed ID: 7705816
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
18. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin.
Nakayama K; Takebayashi Y; Nakayama S; Hata K; Fujiwaki R; Fukumoto M; Miyazaki K
Cancer Lett; 2003 Mar; 192(2):227-35. PubMed ID: 12668287
[TBL] [Abstract][Full Text] [Related]
20. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
